Reply to: Graefe‐Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939–946

Diabetes, Obesity and MetabolismVolume 14, Issue 7 p. 670-670 Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939–946 B. Snyder, Corresponding Author B. Snyder Department of Clinical Pharmacology, Flinders Medical Centre/Flinders University School of Medicine, Bedford Park, South Australia, AustraliaDepartment of Clinical Pharmacology, Flinders Medical Centre/Flinders University School of Medicine, Bedford Park, South Australia 5042, Australia E-mail: B.Snyder@alfred.org.auSearch for more papers by this authorT. M. Polasek, T. M. Polasek Department of Clinical Pharmacology, Flinders University School of Medicine, Bedford Park, South Australia, AustraliaSearch for more papers by this authorM. P. Doogue, M. P. Doogue Department of Endocrinology/Department of Clinical Pharmacology, Flinders Medical Centre/Flinders University School of Medicine, Bedford Park, South Australia, AustraliaSearch for more papers by this author B. Snyder, Corresponding Author B. Snyder Department of Clinical Pharmacology, Flinders Medical Centre/Flinders University School of Medicine, Bedford Park, South Australia, AustraliaDepartment of Clinical Pharmacology, Flinders Medical Centre/Flinders University School of Medicine, Bedford Park, South Australia 5042, Australia E-mail: B.Snyder@alfred.org.auSearch for more papers by this authorT. M. Polasek, T. M. Polasek Department of Clinical Pharmacology, Flinders University School of Medicine, Bedford Park, South Australia, AustraliaSearch for more papers by this authorM. P. Doogue, M. P. Doogue Department of Endocrinology/Department of Clinical Pharmacology, Flinders Medical Centre/Flinders University School of Medicine, Bedford Park, South Australia, AustraliaSearch for more papers by this author First published: 01 June 2012 https://doi.org/10.1111/j.1463-1326.2012.01588.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939–946. 10.1111/j.1463-1326.2011.01458.x CASPubMedWeb of Science®Google Scholar 2 Vincent SH, Reed JR, Bergman AJ et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in human. Drug Metab Dispos 2007; 35: 533–538. 10.1124/dmd.106.013136 CASPubMedWeb of Science®Google Scholar 3 Dhillon S, Weber J. Saxagliptin. Drugs 2009; 69: 2103–2114. 10.2165/11201170-000000000-00000 CASPubMedWeb of Science®Google Scholar 4 He H, Tran P, Yin H et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009; 37: 536–544. 10.1124/dmd.108.023010 CASPubMedWeb of Science®Google Scholar Volume14, Issue7July 2012Pages 670-670 ReferencesRelatedInformation